Overcoming rituximab drug-resistance by the genetically engineered anti-CD20-hIFN-α fusion protein: Direct cytotoxicity and synergy with chemotherapy.
about
Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today's treat-to-target eraPrognostic stratification improvement by integrating ID1/ID3/IGJ gene expression signature and immunophenotypic profile in adult patients with B-ALL.Converting Lymphoma Cells into Potent Antigen-Presenting Cells for Interferon-Induced Tumor Regression.Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance.
P2860
Overcoming rituximab drug-resistance by the genetically engineered anti-CD20-hIFN-α fusion protein: Direct cytotoxicity and synergy with chemotherapy.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Overcoming rituximab drug-resi ...... and synergy with chemotherapy.
@ast
Overcoming rituximab drug-resi ...... and synergy with chemotherapy.
@en
type
label
Overcoming rituximab drug-resi ...... and synergy with chemotherapy.
@ast
Overcoming rituximab drug-resi ...... and synergy with chemotherapy.
@en
prefLabel
Overcoming rituximab drug-resi ...... and synergy with chemotherapy.
@ast
Overcoming rituximab drug-resi ...... and synergy with chemotherapy.
@en
P2093
P2860
P356
P1476
Overcoming rituximab drug-resi ...... and synergy with chemotherapy.
@en
P2093
Benjamin Bonavida
Gabriel G Vega
Héctor Mayani
Luz Areli Franco-Cea
Mario I Vega
Sara Huerta-Yepez
Sherie L Morrison
P2860
P304
P356
10.3892/IJO.2015.3170
P577
2015-09-16T00:00:00Z